Our principal, Ms. Pauli Wong, was invited to speak at the Hong Kong Life Sciences Society (HKLSS) Summer Internship Program 2024 on “Unlocking Patent Law: Exploring IP Career Paths” in July. This program aims to cultivate young talents to drive life sciences innovation. In addition, she participated in the discussion session titled “Evolving Landscape – Investment Outlook for the Healthcare and Life Sciences Sectors” alongside Mr. Tian Tan, the Vice President of NF Trinity.

Pauli shared her career journey becoming a patent attorney at Eagle IP, from an HKU biotech graduate and a scientist with CK Life Sciences. She provided an introduction to intellectual property, particularly patents, and life sciences challenges we are facing, and how to pursue a career path in patent law. By sharing her own experiences, Pauli offered valuable insights and guidance to the aspiring interns to appreciate the importance of IP and consider a career path in patent law.

Our Past Events

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by Managing IP

13 June 2025

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

12 June 2025

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

11 June 2025

Insights from HKSTP Market Discovery - BIO Connect

28 May 2025

HKMHDIA Medical Fair Forum

27 May 2025

Celebrating Innovation at the Asia Summit for Global Health

26 May 2025

Recommended Insights

First ever Invalidation decision on an RNAi Invention patent in China

4 December 2023
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]
Read more >

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

4 January 2023
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]
Read more >

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
Read more >

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

24 May 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Read more >
Top crossarrow-right